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Abstract
The vaccination of children is an extremely important public health
measure which significantly reduced the morbidity and mortality from
various infectious diseases in the last sixty years in Croatia. The Childhood
Vaccination Program in Croatia is based on mandatory vaccinations that
are purchased by the state free of charge. Each year the program is announc-
ed by the Minister of Health based on the recommendations by the Croatian
National Institute of Public Health. Today all Croatian children are com-
pulsory vaccinated against ten different infectious diseases. Although the
program has experienced significant quality improvements in the recent
years, including the introduction of modern, combination vaccines, room
for further improvement and inclusion of new vaccines, despite the complex
economic situation, certainly exists.
INTRODUCTION
Vaccines have been an indispensable and generally cost-effectivetool in controlling infectious diseases for more than a century (1).
Since their introduction, vaccines have played a leading role in the
process of reducing and eliminating vaccine-preventable diseases thus
significantly diminishing human suffering and death. Thanks to active
immunization around 2 million deaths globally have been averted
every year during the last decade (2). Dynamic developments in the
field of vaccine manufacturing in the last 60 years with the introduction
of numerous new effective vaccines not only contributed to the im-
provement of general health and quality of life but also set the tasks to
medical professionals and regulatory bodies responsible for the imple-
mentation of active immunization and approval of vaccination pro-
gram changes (3). The number of vaccines that are mandatory or
recommended for use in pediatric age almost doubled during the last
twenty years (3). The incorporation of any new vaccine into already
crowded immunization schedule is a challenging task. The fact that
nowadays the application of practically all vaccines requires parenteral
route of administration makes this process even more complicated (4).
However, not only technical issues pose a difficulty in modernisation
and expansion of current vaccination schedules. With immunization
programs long established and accepted by health professionals and the
public, reasons for changes have to be well thought-out and docu-
mented. Taking into account primary care facilities and vaccine avail-
ability, demonstrable public health benefit should be the only profes-
sionally and scientifically acceptable reason for making changes (5).
High safety requirements, respect for human rights as well as
strengthening of antivaccinal movements and the presence of false
interpretation of vaccinal side effects further aggravate the process of
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Overview
changing the current vaccination practice, especially in
developed countries (5).
Many vaccines whose long lasting general use was
meritorious for a significant reduction in the morbidity
and mortality caused by infectious diseases were deve-
loped with scarce knowledge on antigenic and immu-
nological interplay between vaccine and vaccinee (6).
Effectiveness in the protection against clinical disease
and safely application have been the essential criteria for
implementing a novel vaccine in the vaccination sche-
dule (6). Modern vaccine development relies on better
understanding of the etiology, epidemiology and patho-
genesis of target disease, as well as the target population
(7). Broadening the knowledge in immunobiology is
essential for the creation of effective and protective new
vaccines (8). Vaccine design builds on a principal con-
cept of induction of protective immunity against specific
pathogen through mimicking of naturally occurring im-
mune response without inducing the disease (8). In con-
trast to older vaccines based largely on whole microbial
pathogens, and to a lesser extent on bacterial toxoids, the
new ones are composed with limited number of highly
purified antigens/epitopes (8). Although »historical vac-
cines« (some of them like BCG, OPV and MMR are still
on the market) supply a broad repertoire of different
epitopes to the macroorganism of which a certain num-
ber provoke immunological response that is not essential
for the protection against the disease, they in general
ensure protective immunity that could be measured through
a significant reduction of morbidity caused by infections
the vaccines were designed against (8). On the other
hand, designing the new, on specific epitopes »concentrat-
ed« vaccines, may pose the risk of insufficient interaction
with individuals missing the adequate immune-receptor
repertoire (8). This fact further underlines the need for
careful and meticulous approach to new vaccine deve-
lopment based on profound understanding of the cel-
lular and molecular elements of the human immune
system involved (7, 8). Antibody-mediated protection is
the cornerstone of successful protective immunity induc-
ed by a vaccine. The quality of antibody-mediated pro-
tection exhibits through affinity and avidity of vaccine
induced antibodies (priming) as well as through persi-
stence of specific antibodies and capability of vaccine to
induce immune memory cells able to reactivate effecti-
vely and rapidly in the presence of new antigen challenge
(9). However, the production of specific, avid and pro-
tective antibodies is not sufficient for the control of all
human pathogens. Stimulating the specific type 1 T-cell
response has considerable role in effective combat against
intracellular pathogens like viruses and Mycobacterium
tuberculosis (6, 9). In those situations antigen-specific T
cells exhibit effector function through targeted removal
of infected host cells establishing control over the repli-
cation of pathogen thus preventing clinically manifest
disease (6, 8, 9).
A better understanding of the human immunological
mechanisms that are crucial for proper response to vacci-
nal antigens and resulting in forming adequate protective
immunity to certain infections is a task to be solved in the
process of creation of a new vaccine. Besides the im-
pressive progress in immunology, a huge number of sig-
nificant technical improvements in biotechnology pro-
cesses of fermentation and purification in the last few
decades have been done thus rendering possible produc-
tion of safer/less reactogenic products (8). Technological
attainments upgraded human vaccinology with nume-
rous new products such as split and subunit influenza
vaccines, acellular pertussis vaccines as well as purified
bacterial polysaccharides (4, 6-9). Although higher puri-
fication of antigens resulted in less reactogenic vaccinal
products, the benefits of high purification are somewhat
lessened through reduced immunogenicity (8). Applica-
tion of multiple doses, adjuvantation and protein-conju-
gate technology have became standard procedures for
overcoming this problem and attaining sufficient and
persistent immunological response that could guarantee
adequate and long-lasting specific protection (9).
All aforementioned achievements in better under-
standing of biological and immunological nature of suc-
cessful vaccination as well as technological improve-
ments in the production process made possible the changes
in routine immunization programs that happened around
the turn of the century. However, the success of this
process does not depend only on the quality of im-
munizing agents but also on the raising of awareness on
benefits of vaccination among medical professionals and
common people (7). Control measures organized and
conducted by national regulatory bodies are essential for
maintenance of the attained levels of safety, efficacy, pu-
rity and potency of the vaccines and they are not less
important than previously listed achievements (7, 10).
The role of regulatory authorities should be even more
conspicuous in new vaccines approval process with spe-
cial emphasis on vaccine safety and possible side effects
(7, 10).
Finally, the importance of well-designed and carefully
implemented communication interventions in support
of immunization should be also emphasized. Commu-
nication is particularly needed to achieve vaccination
coverage in hard-to reach populations and to build trust
in vaccines among those who question them. The im-
pact of well-designed, research-based communication
interventions on achieving health outcomes is indis-
pensable. Without a well-planned, adequately funded
strategic communication, immunization programs fall
short of meeting and sustaining coverage goals (11).
Recommendations for use of a vaccine depend on the
balance between benefits and risks of vaccination versus
risk of disease. The balance must be periodically accessed
(12). Although the development of vaccine schedules
and recommendations begins with prelicensure studies
of a vaccine, an experience gained through its widely use
is immense and should serve as a source of valuable
information that are sometimes decisive in the process of
changing of current vaccinal practice (withdrawal of ro-
tavirus vaccine in the USA after data on intestinal in-
tussusception were obtained, interruption of further
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vaccination with mumps vaccine containing Urabe Am9
strain in England after observation that vaccinal strain
causes aseptic meningitis) (12-14).
CHILDHOOD IMMUNIZATION
PROGRAMS
In all developed countries the recommendations about
vaccination of children have been created under the au-
spices of advisory and/or regulatory national bodies (5,
10, 12). In the United States vaccine recommendations
for children have been developed by two advisory bodies:
(1) the Advisory Committee on Immunization Practices
(ACIP) and (2) the American Academy of Pediatrics
(AAP) Committee on Infectious Diseases (12). The re-
commendations issued by those two committees are re-
vised every two to four years and published as supple-
ments to the Morbidity and Mortality Weekly Report or as a
Report of the Committee on Infectious Disease (Red Book)
(12). In the United States immunizations for children
are provided through both the private and public health
sectors (12). Although no mandatory, but only recom-
mended vaccination exists, high vaccination coverage is
achieved and on the national level at the beginning of the
21st century it ranged from 76.3% for varicella up to
94.3% for diphtheria, tetanus and pertussis (12). How-
ever, it should be noticed that all American states have
laws requiring immunization before school or day care
entry in effect, that, although not officially, in fact con-
vert recommendation into obligation (12). The efficacy
of such organized system of universal continuous vacci-
nation, as in the United States, can be also judged through
the analysis of data on morbidity dynamics of certain
vaccine-preventable diseases through the last century.
Comparing the morbidity of seven different infectious
diseases (diphtheria, pertussis, tetanus, paralytic polio-
myelitis, measles, mumps and rubella) at the end of the
20th century to figures from 1900, a 94% (pertussis) to
100% (paralytic polio) reduction can be observed (15).
In European countries a great difference among vac-
cination schedules, as well as a variety of legislative pro-
cesses can be observed. The wide variation in childhood
vaccination schedules encountered throughout European
Union suggests that they are the result of national tradi-
tions and historical vaccine registrations at the national
level. Immunisation programs are often designed fol-
lowing the agenda of the overall prevention programme
carried out by family pediatricians or well-baby clinics.
Moreover, even the organisation of the school system can
play a role, especially for scheduling boosters in late
childhood and adolescence (16). In the United Kingdom
(UK) all vaccines for childhood vaccinations are free,
purchased by the government and provided by general
practitioners (5). In Scandinavian countries the situation
with the fundings and purchase of vaccines is the same as
in UK. The main difference in comparison to UK is that
in most cases the vaccines are being provided by primary
care nurses (5). In France, pediatricians provide most
childhood vaccines while the cost of vaccination is reim-
bursed from government funds (5). In Germany, vacci-
nes are also provided mostly by pediatricians and reim-
bursement comes from health insurance funds (5). Each
European Union member state has a national advisory
body responsible for vaccines recommendation (5). The
effect of those recommendations varies according to the
centralization of immunization programs and the ba-
lance between public and private sector provision. In
member states with high level of decentralization like in
Austria, Germany, Italy and Spain, national recommen-
dations are modified at the level of autonomous regions/
states because they are the bearers of responsibility for
public health (5). However, not only the degree of the
decentralization plays a role in the final appearance of
vaccination program. Even in unitary state like Sweden
is, although national committee recommends schedule
and type of vaccine, local health authorities have the
right to provide the product they want (5).
In Central and Eastern European countries previous-
ly belonging to the communist block the situation has
dramatically changed at the beginning of the 1990s (5,
17). Some of the countries, like Hungary, Czech Repu-
blic and Slovakia successfully overcame the new circum-
stances and switched vaccines’ procurement from »So-
viet-based« to »Western-oriented« without interruption
in continuous immunization program (5, 17). In Baltic
States the collapse of the Soviet Union caused dissolu-
tion of the immunization system. Since immunization
program was based on vaccines produced in the Russian
Soviet Republic, the downfall of the Soviet federation
caused vaccine shortages. The lack of hard currency
further complicated situation with vaccine purchase
which caused temporarily interruption of immunization
program, fortunately without significant reemergence of
any vaccine-preventable disease. Although significant
changes have occurred in the field of active immuniza-
tion in Central and Eastern European region during the
last twenty years, they remained primarily on technical
(progressive shift to western-produced vaccines) and so-
cio-economic (move from public to private sector-based
medical care) level (5, 17, 18). National control over
designing immunization program and immunization
policy based primarily on mandatory vaccines remained
the two main characteristics of vaccination schedules in
those countries (18).
In a situation where citizenship of the European Uni-
on includes the right to travel, live and work anywhere
within the territory of every member state, a great diver-
sity in vaccination schedules represents an additional
difficulty (16). Starting the vaccination program in one
country and continuing it in another can bring some
challenges: the number of doses, timing, vaccine combi-
nations are different (16). Although, due to the fact that
interchangeability of the vaccines is allowed in most
situations, current differences in schedules are not a real
obstacle to free movement. However, a common sche-
dule can ease the compliance to the national schedule for
foreign citizens and can facilitate the work of health care
personnel that could vaccinate foreign children just accord-
ing to the age, without following complex algorithms
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and recommendations (16). Currently, according to the
European Union regulations, vaccination policies are
exclusively under the patronage of member state autho-
rities, and no central legislation exists (16, 19). Although,
it seems, especially from the doctrinal point of view, that
differences in vaccination schedules between member
states do not represent a significant obstacle in providing
quality health care and maintaining low vaccine-pre-
ventable diseases morbidity, a convergence process with
common schedule as a final goal is highly desirable (16).
The establishing of the European Centre for Disease
Prevention and Control (ECDC), a new European agency
with special mission to identify, assess, and communicate
current and emerging threats to human health posed by
infectious diseases, would maybe be the right address for
commencing activities on harmonization of European
vaccination schedules (20).
In Croatia the program of continuous universal active
immunization of children has been based on mandatory
vaccination against ten vaccine-preventable diseases (21).
The childhood vaccination program that covers life span
from 0 to 19 years of age is based on the recommen-
dations provided by the Croatian National Institute of
Public Health (10). Vaccinations that are enclosed in the
program are obligatory for all children in the defined
target population and are purchased free of charge by the
Croatian Institute for Health Insurance (10). Besides
mandatory vaccination that is perceived as a public health
intervention carrying individual as well as common
benefit through the induction of individual and herd
immunity against certain infectious diseases, in Croatia
there are also recommended vaccinations whose primary
goal is to provide specific protection to people belonging
to specified high-risk populations (10, 22). For pediatric
population this category includes vaccination against





About one third of the world population is infected
with Mycobacterium tuberculosis (22). Tuberculosis (TB)
causes around 2 million deaths each year, of which 450 000
among persons of childhood or adolescent age. The inci-
dence of TB is highest in developing nations, ranging
from 60 to 380 newly diagnosed cases per 100 000 popu-
lation per year. The number of patients is particularly
high in countries with an uncontrolled epidemic of HIV
infection, in which up to 50% of those infected with HIV
also suffer from tuberculosis. In developed countries the
incidence of TB is continuously decreasing and does not
exceed 5 to 8 new cases per 100 000 population yearly. In
Croatia a reduction in TB incidence has been observed
since 1955 when the highest number of newly diagnosed
cases (20 000 cases) has been registered since the end of
World War II (23). The regressive trend has been stopped
during the war time period (1991-1995), although no
increase in the incidence has been observed (23). The
number of patients with TB in Croatia in the last two
decades decreased by three fold – the incidence has de-
clined from 60/100 000 in the early 1990s, to 20/100 000
in 2009 (24). Comparing morbidity rates from different
parts of the country, somewhat higher numbers could be
found in the mainland (15.4 to 39.9 / 100 000) than in the
coastal part of Croatia (9.8 to 21.3 / 100 000) that could be
explained by the differences in climate and longer indoor
stays during winter which stimulates the transmission of
mycobacterium (24). While in developing countries a
significant number of patients with TB are children and
adolescents, in developed countries the incidence of di-
sease among this age group is the lowest (22). In Croatia,
the incidence of TB in children and adolescents in 2009
ranged from 0.8 to 7.0 / 100 000 persons (Table 1) (24). A
favorable dynamics in TB epidemiology in Croatia in the
last half century is certainly the consequence of impro-
vements in socioeconomic conditions, but at least partly
it has to be also attributed to continuous mandatory
vaccination using BCG (Bacillus Calmette-Guèrin) vac-
cine for all children which has been on the market since
1948 (23).
The vaccination against TB in the majority of coun-
tries around the Globe began in 1948 after the First
International BCG Congress in Paris brought the con-
clusion that BCG is effective and safe vaccine despite the
lack of clinical trials in favor of this statement (25). The
data that later on studies gave us mentioned the pro-
tection against less severe forms of disease ranging from
24% to 75% depending on vaccine used, while against
severe forms of disease (disseminated TB and TB me-
ningoencephalitis) BCG shoved immediate protection
in 60% to 95% of vaccinees with duration of protection
not more than 15 years (25, 26). Although the use of the
BCG vaccine has been followed by a certain degree of the
distrust from the very beginning, in the first 25 years of
its usage more than 1.5 billion individuals have been
vaccinated (25).
In Croatia, according to the Childhood Vaccination
Program (CVP) active immunization against TB is man-
datory for all children. Primovaccination is performed by
intradermal application of vaccine in the left deltoid area
within the first year of life (21). All newborns born in
hospitals are vaccinated before they are discharged home.
For those born »extra muros« BCG vaccine is applied
before the end of the 2nd month of life. Those who are not
vaccinated at birth or up to two months of age must be
vaccinated with BCG vaccine by the age of 12 months
(21). Revaccination is performed at the age of thirteen
years only for children with negative tuberculin skin test
(21).
Although vaccination with BCG vaccine is safe and
effective against severe forms of disease, in a situation of
stable declining of TB incidence in Croatia, further vac-
cinations need to be reconsidered when TB incidence
falls to the levels of those in developed countries.
152 Period biol, Vol 114, No 2, 2012.
G. Te{ovi} Childhood vaccinations in Croatia
Vaccination against hepatitis B
Hepatitis B (HB) is a major global public health
problem due to its widespread prevalence and a clear
association of chronic hepatitis B virus (HBV) infection
with liver cirrhosis and hepatocarcinogenesis. The World
Health Organization (WHO) estimates that HBV-asso-
ciated acute or terminal chronic liver disease causes death
in 500 000-700 000 people worldwide annually. WHO
also assess that two billion of people around the Globe
have markers of present/past HBV infection of whom
300 to 500 million remain chronic carriers (27, 28). Po-
pulation of chronic carriers (infected people without any
discernible clinical sign or biochemical marker of disease
activity) represents a significant threat to global health as
a silent but ubiquitous source of infection (27). The in-
tensity of the »HB problem« varies widely from country
to country. Depending on the percentage of chronically
HBV infected people among general population three
different groups of countries can be distinguished: a)
countries with high prevalence of carriers (8% HBs
positives), b) medium-prevalence countries (2–7% of
carriers) and c) low prevalence countries (less than 2% of
carriers) (29). In high-prevalence countries (Sub-Saha-
ran Africa, Pacific region, Southeastern Asia, China, and
Central Asian states) the risk for acquisition of HBV
infection during the life-span exceeds 60%. The infec-
tion is mainly acquired in perinatal period by vertical
transmission from chronically infected women of ge-
nerative age, or during the early childhood through the
contacts with chronically infected family members (27-29).
In medium-prevalence countries the overall risk for acqu-
isition of infection ranges from 20% to 60%. The predo-
minant route of transmission is through close household
contacts and during medical interventions, although
sexual and perinatal transmission should be also kept in
mind. Therefore, the infection could be acquired at any
time during lifetime. In low-prevalence countries (North
America, Western Europe) the overall risk for acquiring
HBV infection does not exceed 20%. Infection mostly
occurs among young adults, and the most important
route of transmission is through sexual intercourse (27).
In those countries HBV infection more frequently affects
people belonging to certain risk groups (chronic carrier’s
sexual partners and household members, parenteral drugs
users, promiscuous heterosexuals and male homosexuals)
as well as persons that professionally or during medical
treatment (especially patients on hemodyalisis, hemo-
philiacs and cancer patients) come into contact with
blood and blood products. A special risk occurs for new-
borns born to chronically infected mothers in whom
vertically transmitted infection in more than 90% evolves
into chronic disease/carrier state (27-29).
Croatia belongs to low-prevalence countries with less
than 2% of chronically infected population (30, 31). In
the last decade the number of newly diagnosed HBV in-
fected patients did not exceeded 220 patients per year, with
the lowest number registered during 2010 (58 subjects)
(24). The number of newly registered chronic carriers in
the same period ranged also around 200 cases annually
(30, 31).
The best way to prevent HBV infection is active im-
munization (32). Since previously declared WHO doc-
trine of vaccination for just those subjects belonging to
high-risk populations for acquisition of HBV infection
didn’t show any significant decrease in the morbidity, a
new recommendation on universal vaccination in child-
hood has been issued (33). The majority of nations adopt-
ed WHO recommendation starting with infant immuni-
zation, while a lesser number, including Croatia, de-
cided to start immunization at a preadolescent age (32).
The decision was based on epidemiological data show-
ing a small number of HB cases in children and a peak
incidence of disease among young adults (32). The pre-
existing practice of vaccinating all newborns born to HBs
positive mothers was taken as an additional evidence for
the justification of this decision. However, clinical data
showed that the implementation of such a strategy has
some faults and that certain number of young children,
mainly those with chronic conditions and hematoon-
cologic disorders remained unprotected and acquired
HBV infection (34). The vaccination against HB in
Croatian children started in 1999 with vaccination of all
sixth graders using three doses of recombinant DNA
vaccine schedule (34). However, starting with the year
2007 the vaccination was moved to the neonatal age (35).
According to the Croatian National Institute of Public
Health (CNIPH) data for 2010, the vaccination coverage
for HB in neonatal age was declared 97.0% (24).
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TABLE 1
The incidence of TB in Croatian children and adolescents (2000 – 2009)*
Age The incidence of TB in Croatian children and adolescents aged 0 – 19 years (number of patients/100 000)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
0-4 y 4,9 2,6 6,3 2,5 2,9 0,8 2,1 2,1 2,1 0,8
5-9 y 6,3 6,7 7,6 10,9 6,0 4,0 2,8 3,6 2,0 3,2
10-14 y 11,5 11,2 12,7 11,5 8,2 5,2 6,3 3,7 6,3 5,6
15-19 y 15,2 16,2 12,4 13,1 14,4 11,1 9,4 7,4 6,4 7,0
*According to data from: CROATIAN NATIONAL INSTITUTE OF PUBLIC HEALTH 2010 Croatian Health Service Yearbook 2010. Available
from: http://www.hzjz.hr/publikacije/hzs_ljetopis/index.htm
Recombinant vaccine that is in use in CVP in Croatia
is immunogenic, effective and safe vaccine (36). The
protection against HBV infection is directly related to the
creation of anti-HBs antibodies. Antibody titer of >10
mIU/mL measured 1-3 months after administration of
the last dose of vaccine is considered a reliable marker of
short and long-lasting protection against natural infec-
tion (37). Immunological response to vaccination could
be modified even by vaccine injection site. In newborns
and infants vaccine should be applied by intramuscular
injection in mediolateral aspect of the thigh (32). The
application of HB vaccine concomitantly with other in-
activated and live-attenuated pediatric vaccines seems
not to have an effect on the immunogenicity of HB
vaccine as well as the coadministered vaccine (36).
The exact duration of protection after vaccination
with HB vaccine is not known, although 15% to 50% of
children vaccinated in infancy lose detectable antibody
levels within 5 to 15 years after vaccination (32, 36).
However, no clinically manifested disease caused by HBV
among immunocompetent children has been observed,
while only few cases of chronic HBV infection have been
documented (36). Basing on those data, currently there
are no recommendations for routine booster doses of HB
vaccine as well as for periodic serologic testing (36).
Generally, recombinant HB vaccine is a safe vaccine.
More than 90% of vaccinees don’t manifest any side
effects. Pain at the injection site (3% to 5%) and mildly
elevated body temperature (1% to 6%) are the most fre-
quently reported side effects. Rarely fatigue, nausea, flu-
-like illness, vomiting, dizziness, pruritus, arthralgia and
diarrhea have been registered (36-38). Although a variety
of chronic diseases have been reported following HB
vaccination, including demyelinating disorders (multiple
sclerosis, optic neuritis, transverse myelitis), rheumatoid
arthritis, type 1 diabetes and chronic fatigue syndrome,
no definitive findings supporting these hypotheses have
been found (36, 38).
Vaccination against diphtheria
Diphtheria is among rare infectious diseases that is
eliminated in Croatia, and since the last case of this
indigenous disease was registered almost 40 years ago
(1974) there is also a belief, although unsupported by
results of research, that its causative agent is even era-
dicated (39). A favorable trend that led to the disap-
pearance of diphtheria from Croatian population is cer-
tainly the result of continuous implementation of uni-
versal vaccination of children with diphtheria toxoid (D)
since 1947 (39). A similar epidemiologic pattern has been
observed in all other countries that implemented D in
their vaccination schedule (40). Although no modern
designed study dealing with immunogenicity and efficacy
of D has been available, it is obvious from epidemiologic
data that D has good protective effect against clinically
manifested disease (40). It is generally accepted, partly
based even on the results from animal studies, that diph-
theria antitoxin level of less than 0.01 IU/mL is not
protective. Vaccinees with antitoxin level ranging from
0.01 to 0.09 IU/mL are partly protected, while the con-
centration 0.1 IU/mL provides full protection (39, 40).
The other important question is the duration of protec-
tive immunity. According to data from England, less
than 30% of people aged more than 60 years have detect-
able protective level of antitoxin (39). A Croatian study,
although limited with low number of collected sera,
showed the presence of partly protective levels of anti-
toxin in 66%, while fully protective level was found in
33% of subjects older than 60 years (39).
There are two important questions regarding the vac-
cination against diphtheria: 1) is there a need for booster
doses in elderly people who lost specific protection and
2) do we still need continuous vaccination against diph-
theria if the disease has been eliminated from the po-
pulation. Regarding boostering the adults or elderly
people it is postulated that in spite of low levels of im-
munity among those age groups, diphtheria will remain
well controlled with effective childhood immunization
(40). On the other hand, since the causative agent of
diphtheria is still present in certain populations, ceasing
the immunization could result with reemerging of diph-
theria among populations with long-lasting state of eli-
mination. »Russian epidemics« in the early 1990s with
more than 100 000 cases after the interruption of vac-
cination due to dissolving Soviet immunization program
is a relatively recent argument for continuing the vac-
cination (39, 40).
Vaccination against tetanus
Tetanus is unique among vaccine-preventable diseases
because it is not communicable (41). Around 1 million of
people every year acquire tetanus worldwide (42). In
developing countries, especially in some parts of Eastern
Africa and Middle East, neonatal tetanus accounts for
50% of cumulative number of cases (42). The causative
agent, Clostridium tetani, is ubiquitous microorganism,
widespread in the environment. Clinical manifestations
of disease develop as a consequence of entering clostri-
dial spores into a devitalized human tissue usually in the
vicinity of cutting or stab injuries. Anaerobic/microaero-
phylic conditions typical for such injuries stimulate ger-
mination of spores to vegetative bacili that elaborate
toxin responsible for the development of disease symp-
toms (41, 42). Isolation and purification of toxin and its
inoculation into experimental animals facilitates further
studies of disease pathogenesis, but also the production
of animal sera to be used in prevention/treatment of
tetanus in humans (41, 42). First attempts to stimulate
specific immunity against tetanus in humans were made
in 1917 when Vallee and Bazy immunized seven heavily
wounded French soldiers of African ancestry with chemi-
cally modified (iodine treated) tetanus toxin (43). Although
effective, further investigations on iodine inactivated teta-
nus toxoid were abandoned (43). Preparation of »ana-
toxin«, latter called »toxoid« (T) – with formaldehyde
inactivated but immunogenic tetanus toxin, marked the
beginning of an era of modern active immunization
against tetanus (41-43). Clinical application of formal-
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dehyde inactivated T began in 1926. Preventive wide-
spread usage of this vaccine during the World War II
decreased the incidence of tetanus among wounded Ame-
rican soldiers by 30-folds (from 13,4 cases of tetanus per
100 000 wounds in World War I to 0,44 cases per 100 000
wounds in World War II) (42).
Tetanus toxoid was introduced in many vaccination
schedules during the 50s (43). Immunization against
tetanus has been implemented in Croatia since 1955
(42). In 1965, the WHO standardized the calibration of
the potency of T containing vaccines and established the
first international standard for T (41). New WHO po-
tency standards for T-based vaccines were set in 1982,
since when 40 IU preparations (60 IU when in com-
bination with D and/or pertussis vaccine) have been
used (41). Although widespread use of T began with
single-component vaccines, today tetanus toxoid when
used in childhood immunization schedules is usually
incorporated in diphtheria-tetanus-pertussis combina-
tions or even more advanced versions (41-43). T-based
vaccines used as a single vaccines or in combinations are
stable, immunogenic and with low reactogenicity (41).
National-based Danish study dealing with the problem
of duration of specific protection after completing pri-
moimmunization against tetanus in childhood showed
persistence of protective levels of antitoxin for 14 years in
96% of vaccinees and for even 25 years in 72% of them
(41). Studies from Sweden and USA found a 10-year
persistence of protective antitoxin levels in around 90%
of vaccinees. Based on these results, the majority of na-
tions worldwide advise life-long boostering every 10 years
(41). CVP in Croatia uses in total eight doses of tetanus
for primovaccination and boostering – after finishing
primary series in their first year of life, Croatian children
will be vaccinated with one dose in the second and fourth
year of life and boosted twice during the elementary
school and finally at the age of 19 (21).
Vaccination against pertussis
Despite being greatly reduced by vaccination, per-
tussis is still present as an endemic and epidemic disease.
In countries with long-lasting history of continuous vac-
cination against whooping cough, the disease mainly
occurrs in atypical form in adolescents and young adults
or as a severe disease of unimmunized or partially im-
munized infants accompanied with high rate of compli-
cations and even unfavourable outcome (44-46). Pertu-
ssis occurs in periodic cycles approximately every two to
five years. This typical epidemic pattern is preserved
even in countries with low incidence due to high vac-
cination coverage (47, 48).
Although the first attempts to introduce vaccines
against whooping cough occurred immediately after the
discovery of the pathogen in the early 1900s, the era of
active immunization against pertussis began in 1947
with the introduction of a combined vaccine against
diphtheria, tetanus and pertussis that contained D, T
and inactivated whole cell of Bordetella pertussis (DTwP)
in the US childhood vaccination schedule (49). In the
next two decades DTwP became part of the recommend-
ed immunization schedules for children in all developed
nations. Active immunization against whooping cough
using domiciliary produced vaccine in Croatia began in
1959 (47, 50, 51). In the early 1960s, the WHO has set
international standards to be met by every pertussis vac-
cine. Each vaccine dose had to contain at least 4 interna-
tional units (IU) of B. pertussis. One IU corresponded to a
concentration of one billion microorganisms per milli-
liter of vaccine (47, 49, 52). The average concentration of
inactivated B. pertussis in the Croatian vaccine corres-
ponded to the total dose of 12-30 IU for the entire primo-
vaccination, or an average of 20 IU in three doses which
made the Croatian DTwP vaccine acceptable for inter-
national standard (52, 53). Epidemiological studies that
have been conducted prior to the introduction of DTwP
in immunoprophylaxis of whooping cough, as well as
field studies performed after the introduction of the vac-
cine into the routine use have shown good effectiveness
of vaccines in many countries. Compared with non-
immunized population, the vaccine, depending on the
country where the research was conducted, showed an
effectiveness of 63% to 94.8% if it was applied to infants
in three consecutive doses (47, 52). In most countries
vaccination schedule in the first year of life comprised
application of three vaccine doses starting at the age of 2
or 3 months of life, with 4 to 6 weeks intervals between
the doses applied (47, 52). From the beginning the dif-
ferences in the number and time of application of booster
doses existed. Some countries along with an early booster
at 18 months of age applied the second one at the age of 4
years (Argentina, Croatia, The Netherlands, United King-
dom) while others disposed the second booster to the
time of primary school enrollment (Australia, Canada,
USA, Spain, Switzerland) (48, 50). Regardless of the
differences in the vaccination schedule and number of
booster doses, active immunization against whooping
cough using DTwP vaccine has dramatically changed
the classical epidemiological shape of the disease and has
achieved an impressive reduction in morbidity and mor-
tality (47, 50). In Croatia, the continuous application of
DTwP with coverage rate of 80% in the primovaccina-
tion and 90% for booster doses reduced the number of
cases of whooping cough in the first 20 years of universal
vaccination for 94.4% in comparison to the prevaccinal
period (50). Although doubtless effective in preventing
disease, systematic monitoring clearly showed that the
universal use of DTwP modified conventional epidemio-
logical pattern of disease with a shift of morbidity in
younger and older age groups. Frequent side effects, even
some infant deaths in the US, UK and Japan were also
observed (47, 48, 54-57). Although neither naturally ac-
quired infection doesn’t leave lifelong immunity, specific
immunity after vaccination with DTwP, regardless of the
number of booster doses applied, is limited to the period
within no more than 12 years after the application of the
last dose (58). A direct consequence of the limited dura-
tion of protection in highly vaccinated populations is the
frequent occurrence of pertussis among adolescents and
adults. Adolescents and young adults thus serve as a
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reservoir of infection for unimmunized or partially im-
munized young infants (56, 58).
DTwP reactogenicity was observed soon after the in-
troduction of vaccine in general use. Local reactions at
the site of vaccine application were the most common
while the generalized side effects such as fever, prolonged
unexplained crying, seizures and hypotonic-hyporespon-
sive episodes (HHE), were less frequent and had not
discouraged further implementation of DTwP (47). A
continuous decline in the incidence of pertussis in coun-
tries with high vaccine coverage further justifies this
perception (45, 47). In the early 1960s the first reports
linking the use of DTwP with progressive encephalo-
pathy, infantile spasms, and sudden infant death syn-
drome (SIDS) appeared (47, 59, 60). Although these side
effects were very rare, and there is even a reason to doubt
their direct connection with the vaccines, their occurren-
ce in some countries (Japan, Sweden, United Kingdom)
completely disrupted the implementation of DTwP (47,
61, 62). The direct consequence was reemergence of
epidemic disease with a high number of hospitalizations,
and even deaths (61, 62). Faced with the renewed threat
of epidemic pertussis, but also with the resistance of the
public and the medical authorities to DTwP, during 1970s
and early 1980s vaccine manufacturers have invested
considerable effort and resources into creating a new,
acellular pertussis vaccine (aP) (63). The first country
that introduced the aP into routine immunization was
Japan in 1981. After a large number of field trials, from
the beginning of 1990s the aP became a part of the
immunization schedule in many European countries,
Canada and the United States (63, 64). The development
of aP vaccines went through several phases, starting from
monocomponent vaccine containing only pertussis-toxin
(PT), through two-component vaccines containing PT
and filamentous hemaglutinine (FHA) to modern aP
containing three – PT, FHA and pertactine (PRN) to
five components (PT, FHA, PRN and two types of
fimbriae – FIM) (63, 64). The effectiveness of these
vaccines, depending on the number of included
components ranges from 59% to 93% (63). Since the
reactogenicity of aP vaccine is much lower than that of
wP, effectiveness approximately equal, and duration of
protective immunity not significantly shorter (6 years
after the last dose), multicomponent aP vaccine is now
preferred to wP-based vaccines (65, 66). However, the
introduction of aP did not resolve the question of dis-
placement of pertussis morbidity to the youngest and
older age groups (54). A possible solution is the vac-
cination of adolescents, as well as vaccination of certain
adult populations, such as young mothers and new-
born’s household members („cocoon strategy”), health
professionals and day-care staff members (54, 58). Another
possibility for better control of disease burden in a popu-
lation is periodic boostering of the whole adult popula-
tion. However, even in most developed nations this stra-
tegy seems far from implementation.
Vaccination against poliomyelitis
Although the first written description of poliomyelitis
dated from very ancient times of Egyptian XVIIIth dy-
nasty, poliomyelitis has remained for long time an ende-
mic disease that crippled limited number of subjects
(67). At the turn of the 19th into 20th century, a change in
the epidemiology of poliomyelitis from endemic to an
epidemic form was observed in many industrialized
European nations, and then in the US and Canada (67).
The epidemics of polio reached their peak after the end
of Word War II with more than 20 000 cases of disease
reported annually in the US associated with high case-
fatality rate (68). In Croatia at the beginning of the 1960s
major epidemics were also registered with more than 600
cases occuring annually (69).
The discovery of the virus, definition of three diffe-
rent serotypes, confirmation that neutralization antibo-
dies protect against the disease and finally demonstration
that all three serotypes could be grown in cell cultures of
non-neuronal origin were crucial steps in the develop-
ment of the first effective vaccine against poliomyelitis
(67, 68). In 1954 the first trivalent poliovirus vaccine
inactivated by formalin (inactivated polio vaccine – IPV)
was designed by Jonas Salk. Its effectiveness and
reactogenicity were tested in one of the largest vaccine
field trials that comprised 419 000 vaccinees and 330 000
controls. Since the results of the study were promising,
IPV was licensed for widespread use in the US next year
(68). After the IPV introduction in pediatric vaccination
schedule in US, a sharp decline in the number of cases
has been observed very soon – three years after the be-
ginning of the widespread use of IPV an 86% reduction
in the incidence of poliomyelitis in USA was registered
(67). Although the impact of IPV on the epidemiology of
polio was impressive, in the early 1960s IPV was eclipsed
by new attenuated live oral polio vaccine (OPV), except
in some northern European countries (Finland, Sweden,
the Netherlands) (67). The OPV era started in the US
with licensure of monovalent OPV in 1961, and then
trivalent OPV in 1963 (67, 68). However, the first large-
-scale production, the first large safety and efficacy field
trials, as well as the first mass immunization campaign
took place in the former Soviet Union (67). First results
were impressive – incidence decreased from 10.6/100 000
population in prevaccine era to 0.43/100 000 population
in the third year of OPV universal implementation (67).
In Croatia, compulsory vaccination against polio was
introduced in 1961 using monovalent Koprowsky’s OPV
vaccines. During the two year period the whole popu-
lation aged less than twenty years of age were fully vac-
cinated (69, 70). In 1964 the compulsory boosters were
introduced for all children in the 3rd and 5th year of life,
as well as for elementary school 1st and 4th graders (69).
In 1965 a new booster for 14-year-old children was intro-
duced while booster in the 4th grade was abandoned
(69). In 1983 Koprowsky’s vaccine was switched to tri-
valent Sabin OPV (69). Systematic and universal use of
OPV in Croatian population, with coverage rates be-
tween 73% and 80% for primovaccination and 90% for
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boosters, has very soon shown impressive results – twelve
years after the introduction of OPV for the first time not a
single case of paralytic polio was diagnosed (69). The last
epidemic was registered in 1984 and the last sporadic
case in 1989 (69, 71).
Although there is no doubt that systematic and wide-
spread use of OPV was the main contributory factor in
the eradication of wild polio infection from three major
WHO world regions – Americas, Europe and Western
Pacific, soon after the introduction of OPV in national
immunization programs the first cases of vaccine-as-
sociated disease were recorded (67, 69, 71). Although rarely
seen, vaccine-associated paralytic poliomyelitis (VAPP)
and vaccine-derived poliovirus (VDPV) disease pose
continuous risk associated with OPV use (72, 73). That
was the main reason why WHO suggested that OPV
should be replaced by IPV in post-eradication era (74).
Good effectiveness and appropriate duration of specific
immunity showed in some European countries with long-
-lasting experience in IPV usage, as well as its ease in-
corporation into combination vaccines further facilitated
the (re)introduction of inactivated vaccine into immu-
nization schedules of numerous nations (67). In Croatia
OPV was completely replaced by IPV in 2008 (35).
Vaccination against Haemophilus
influenzae type b disease
Before the introduction of effective vaccine against
the Haemophilus influenzae type b (Hib) this bacteria
was the leading cause of acute bacterial meningitis among
infants and children younger than 5 years of age world-
wide (75). At the end of the 1980s 20 000 to 25 000 US
children developed invasive Hib disease, mainly acute
meningitis, annually. The incidence and mortality of
Hib disease among US children were thus similar to
those caused by polio virus before the introduction of
universal vaccination (75). Data on invasive Hib disease
from Croatia are scarce and incomplete primarily due to
the fact that significant number of microbiologic labo-
ratories had never performed serotyping of Haemophilus
spp. isolates from primary sterile sites. According to data
collected from the University Hospital for Infectious Di-
sease (UHID) in Zagreb that covers Zagreb metropoli-
tan area (around one fourth of the total Croatian popu-
lation) the incidence of invasive Hib disease before the
introduction of universal immunization was around 22
cases per 100 000 children aged less than 5-years, with
mortality of 3.3% (76). After the introduction of manda-
tory vaccination against Hib in Croatia, although the
»catch-up« immunization of all susceptible subjects
(younger than 5 years of age) was not performed, the
incidence sharply decreased as was previously seen in
other populations that implemented universal vaccina-
tion of all children (76). In 2009 no Hib invasive disease
was diagnosed at UHID, and in 2010 one case of bacte-
remic pneumonia in nonimmunized 10-year-old girl was
registered (76).
Although several surface structures of Hib appear to
be important in its pathogenicity, the outermost struc-
ture, polysaccharide capsule that consists of a repeating
polymer of ribosyl and ribitol phosphate (polyribosylri-
bitol phosphate, PRP) is crucial for invasiveness of Hib
(75). Natural immunity to Hib resists on anticapsular
antibodies. Maternally acquired antibodies still present
in infants younger than 6 months of age, and the natural
acquisition of antibodies in toddlers and children aged 2
to 5 years are responsible for typical epidemiologic pat-
tern of invasive Hib disease with peak incidence in the
age range from 6 months to 2 years of age, as well as the
disappearance of disease after the age of five (75). Although
a precise minimal level of anti-PRP antibody that is
protective has not been established, data from passive
protection of agammaglobulinemic children as well as
from studies on naturally acquired antibodies, suggest
that minimal serum concentration of anti-PRP antibody
that provides protection in humans is 0.15 µg/mL, while
the concentration of more than 1.0 µg/mL guarantees
protection for a minimum of one year (75). PRP, as a
typical polysaccharide that consists of repeating oligo-
saccharide units, is primitive antigenic unit that elicits
weak immune response involving minimal T-cell influ-
ences (75). Upgrading of PRP immunogenicity in
infants could be made by switching from T-cell indepen-
dent to T-cell dependent antigen through the process of
conjugation (75). PRP conjugated to protein carrier
(diphtheria toxoid, tetanus toxoid, meningococcal outer
membrane protein) could elicit adequate immunologic
response characterised by switching in immunolo-
globulin classes (IgM to IgG), appropriate avidity of
specific antibodies and memory capacity needed for ade-
quate booster effect (75). Among all Hib-conjugate vac-
cines, PRP-tetanus toxoid conjugate vaccine (PRP-T) is
most widely used. PRP-T showed excellent immuno-
genicity, with seroconversion rates of 98% to 100% after
the third primovaccination dose, achieving mean anti-
-PRP antibody concentrations of 5 to 10 µg/mL and
persistence of good antibody levels a year after immu-
nization (75). The vaccine is generally well tolerated.
Local mild side effects were registered in 7% to 15%,
while fever higher than 38°C occurred in less than 10% of
vaccinees (75). Efficacy of PRP-T is showed on pre-
licensure studies and during the universal use of vaccine.
In all countries that implemented Hib vaccine in their
universal immunization program, invasive Hib disease
disappeared from the population (75, 76).
DTaP-based combinations
Inauguration of new inactivated vaccines in the pe-
diatric vaccination schedule is firmly connected with the
development and promotion of usage of combined vac-
cines. The development of combined vaccines has been a
public health interest and priority, and their use is recom-
mended by the WHO. The usage of combined vaccines
minimizes the number of injections, reduces the cost of
vaccination program and increases the compliance (77,
78). However, it is important to ensure that safety, im-
munogenicity and efficacy of combinations are not in-
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ferior in comparison to individual components when
applied separately (77, 78).
DTaP-based combinations are cornerstone of modern
immunization programs and the majority of nations use
pentavalent (DTaP-IPV-Hib) or even hexavalent (DTaP-
IPV-Hib-HBV) combinations (79, 80). Pentavalent
combination containing D, T, five-component aP (PT,
FHA, PRN, fimbriae type 2 and 3), IPV and PRP-T was
introduced in the Croatian CVP in 2008 and used until
2011 (24, 35). The introduction of this »new« penta-
valent combination represented a major shift in CVP in
Croatia – for the first time IPV instead of OPV and aP
instead of wP were introduced (35). Although some local
experts expressed doubts regarding the effectiveness of
these new vaccines, judging through the data provided
by the CNIPH, a switch from the »old« to »new« vac-
cines didn’t disarrange the stable epidemiological situa-
tion in Croatia (24). Compared to previous period when
wP was in use, the number of patients with clinically
diagnosed whooping cough continued to fall (45 cases in
2010 vs 123 in 2007) (24). Although obviously good
vaccine, the usage of pentavalent combination intro-
duced in 2008 was suspended at the end of 2011, and the
vaccine was substituted with the »new« pentavalent
combination containing the same components as the
previous one except the aP which is a two-component
(PT and FHA) (21). The currently used combination
has been extensively assessed in clinical studies testing its
safety and immunogenicity in a primary series of vac-
cinations as well as a booster in the second year of life (79,
81). The vaccine is well-tolerated and its application is
associated with predictable side effects that are generally
mild to moderate. Good immunogenicity was shown to
all antigens comprised in vaccine in both primary vac-
cination series and boostering. In national immuniza-
tion programs where combination with two pertussis
antigens is in use, good control of pertussis incidence has
been shown (79, 81).
Vaccination against measles
Before the active immunization became available,
measles was ubiquitous, highly contagious, seasonal viral
disease affecting nearly every person in a given popula-
tion by adolescence (82). In the ten years period from
1958 to 1967 an average of 12 000 children suffered from
measles in Croatia annually (83). First efforts to reduce
the morbidity thus preventing early and late compli-
cations of disease have been undertaken soon after the
discovery of the infectious agent (82). After the unsuc-
cess of formalin-inactivated vaccine that produced the
short-lived immunity and placed many recipients at risk
for atypical measles, the first live-attenuated vaccines
derived from Edmonston B strain of virus have been
licensed in the mid 1960s (82). In Croatia lesser cam-
paigns of vaccination with Edmonston B vaccine began
in 1964, while universal vaccination using domiciliary
produced Edmonston-Zagreb (EZ) vaccine became
mandatory in 1968 (83). In the first six years of its usage,
Croatian children were vaccinated with one dose of
live-attenuated vaccine at the end of first year of life, or in
the ages of 7 to 10 years of life (83). From 1975 onward
two doses of vaccine were applied – first at the age of 12
months and the second for elementary schools’ first-
graders (83). The law passed in 1975 provided that vac-
cinal coverage against measles must be above 85% (84).
This demand was in 1980s increased to 95% (85). The
success of a universal mass vaccination of children in
Croatia against measles soon became clearly visible. The
number of cases in the 1976 to 1985 period dropped to
3345 annually which represented a reduction in the
incidence for 72,3% (83). Continuous vaccination using
two-doses schedule further reduced the incidence – in
the 5-year period (1997-2001) the mean annual mor-
bidity dropped to 187 cases that represented a 98.8%
reduction in comparison to prevaccinal data (86). In the
first decade of the 21st century the disease practically
disappeared from Croatian population – less than ten
cases annually were registered in seven out of ten years,
with no cases diagnosed in 2007 (24). In the same period
the vaccination coverage for primovaccination and
revaccination exceeded the statutory defined 95% (24,
87). However, in a situation in which WHO’s goal laid
out in the strategic plan for measles elimination from the
European region by 2010 has not been achieved and
when despite the high vaccine coverage in some coun-
tries the minimum immunity level is still under the
defined percentage that guarantees the interruption of
virus transmission, the reintroduction of wild measles
infection into a population remains a real threat (87, 88).
In the last decade several European countries reported
high number of cases and outbreaks, mainly in unim-
munized or partially immunized people. One fifth of
cases were subjects older than 20 years of age (88). In the
same period, in Croatia two imported epidemics with 54
and 49 cases were noted (24, 87). The last one that
occurred in spring 2008 caused by virus belonging to
genotype D4 was probably imported from Italy where
significant disease activity was observed during the nine-
-months period from early autumn 2007 to spring 2008
(89). The majority of Croatian cases, as well as Italian
ones were registered among partially immunized or fully
unimmunized young adults (87, 89). The data from the
last European epidemics thus underscore the need for
further strengthening of high two-dose regimen vac-
cination coverage as a unique strategy in successful com-
bat against measles.
Active immunization against measles in Croatia for
many years relied on local vaccine production (83). Do-
mestic vaccine contained EZ strain was prepared from
the original Edmonston B strain by additional passage
on WI-38 cells (90). Used as a monovalent vaccine or as a
component of combined vaccine against measles, mumps
and rubella (MMR), EZ showed low level of reacto-
genicity, seroconversion after primovaccination in 99.3%
of vaccinees with HI titers 1:8 in 96.1% of them and fair
persistence of sustained seropositivity (83, 91). From
2009 a new MMR vaccine containing another Edmon-
ston B derived strain (Schwarz) was introduced for pri-
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movaccination, while MMR combination containing
Enders strain was implemented for revaccination at the
age of 7 years since 2012. According to experience from
other countries both vaccines provide good protection
against measles when used in two-dose schedule and
both show low level of reactogenicity (82). However,
further surveillance of epidemiologic situation and side
effects of vaccines are necessary (92).
Vaccination against mumps
Mumps is an acute systemic viral disease caused by
mumps virus (MuV). In prevaccinal era mumps usually
occurs in school-aged children and adolescents (93). Since
no etiological treatment of mumps exists, and compli-
cations, especially in the CNS, are frequent, active im-
munization remains as the only possibility to control
MuV spread and thus reduce morbidity (94). Conti-
nuous universal usage of vaccine with sustained high
coverage rates may even lead to complete eradication of
the disease from the population (95). The definition of
the etiologic agent and then first successful propagation
of MuV in chicken embryo and tissue culture allowed
cultivation of large amounts of virus and creation of a
basic prerequisite for the development of vaccine (96).
The first inactivated vaccine developed in 1950 in the
United States originated short-lasting specific immunity
and in epidemic situation it was proved ineffective (96,
97). Enders and co-workers discovery that during conti-
nuous passage in embryonated chicken eggs MuV loses
pathogenicity but not immunogenicity enabled the
commencement of work on the preparation of the first
live attenuated vaccine against mumps (96). The first
live attenuated vaccine that has entered into wide use,
was produced in 1954 in the Soviet Union and has suc-
cessfully been applied in children and adults (98). Viral
strain contained in this vaccine developed in embryonated
chicken eggs, marked with the name Leningrad became
the parent strain for all subsequent mumps vaccines
produced in the Soviet Union (96). Using Leningrad
strain the first vaccine produced in cell culture was sub-
sequently developed. After the initial passages on pri-
mary culture of guinea pig kidney, vaccinal strain was
adapted to the quail embryo fibroblasts. The first mo-
dern live attenuated vaccine against mumps was thus
created. This vaccine was highly immunogenic stimulat-
ing production of neutralizing antibodies in more than
96% of vaccinees (96). Simultaneously efforts under-
taken in the US resulted in the creation of successful
vaccinal strain – Jeryl Lynn (JL). First vaccine contain-
ing JL was licensed in 1967 (99). Within the next twenty
years other vaccinal strains were developed: L-Zagreb,
Urabe Am9, Hoshino, Torii, Rubini and RIT 4385 (98,
99). In Croatia vaccinal strain L-Zagreb (LZ) was creat-
ed during 1970 and 1971 through additional attenuation
and adaptation of Leningrad-3 strain on chicken fibro-
blasts primary cultures (100). The monovalent vaccine
contained LZ was introduced into Croatian CVP in
1972, and since 1975 MMR vaccine with LZ as a mumps
component became mandatory for all Croatian children
(99, 100). In 1994 two-dose schedule with the first dose
applied at the age of 12 months and the revaccination at
the age of 7 years was introduced (101, 102).
Live mumps vaccine stimulates the production of a
number of antibodies to different MuV epitopes that can
be measured by different serological techniques and re-
sults are regularly expressed through seroconversion rate
(103). Neutralizing antibodies against hemaglutinin (HN)
are probably of the paramount importance and their
presence correlates with protection against the disease
(103, 104). Data on seroconversion for all mumps vac-
cines showed favourable results ranging from 86.6% to
100% (103). LZ vaccine caused seroconversion in 88% to
94% of vaccinated preschool-aged children. Seroconver-
sion was even better (98%) in children vaccinated with
MMR containing LZ (100). A single study performed in
Croatia showed the presence of neutralization antibo-
dies against HN in 96% of the vaccinees (105). The
duration of specific immunity is also of crucial impor-
tance in the protection against the disease. Seroreversion
measured by neutralization test developed in 19% of JL
vaccine and in 15% of Urabe Am9 recipients four years
after the vaccination (103). In infants immunized with
RIT 4385 neutralization antibodies persisted in 95% of
vaccinees 18 months after the primovaccination (103).
For LZ data on antibody persistence are rather scarce. A
single study performed in Croatia showed no detectable
antibodies against MuV in 17.4% subjects 18 to 19 years
of age vaccinated with single dose of LZ vaccine at the
age of 12 months (101).
Although data on immunogenicity and duration of
specific immunity are somewhat confusing due to dif-
ferent serologic techniques used and different time inter-
val between vaccination and determination of seroposi-
tivity, maybe a better picture of the real situation could be
obtained through the results of efficacy trials and effecti-
veness in the field use of vaccine. All widely used vac-
cines with the exception of Rubini showed efficacy in
range 91% to 99% and effectiveness between 79% and
100% (103).
Prelicensure clinical studies of different mumps vac-
cines reported only mild to moderate local reactions and
rarely occurrence of general symptoms, usually mild fe-
ver of short duration, rash and salivary glands swelling.
However mass usage of vaccines has shown a true scope
and intensity of reactogenicity of certain vaccine strains
(106). Through more than four decades of widespread
live attenuated mumps vaccine usage, many undesirable
side effects have been attributed to the vaccine, with
more or less clear evidence of causal relationship (106).
Insulin dependent diabetes mellitus, inflammatory bo-
wel disease, autism, idiopathic thrombocytopenic pur-
pura, aseptic meningitis, Guillain-Barrè syndrome and
cerebellar ataxia have all been associated with vaccina-
tion against mumps (98, 106-111). Especially great con-
cern and fear aroused Wakefield’s report from Great
Britain that vaccination against mumps correlates with
the development of inflammatory bowel disease and an
increase in the incidence of autism (107). This report
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resulted with almost complete cessation of vaccination
with MMR vaccine in the UK (106, 107). However, the
results of the study were based just on epidemiological
observations and studies that followed did not confirm
Wakefield’s conclusions (112, 113). Analyzing huge
number of papers dealing with the problem of side effects
that have been attributed to vaccination against mumps,
Jefferson and colleagues in a large meta-analysis pub-
lished in 2003 have found that only two side effects could
be undoubtedly causally linked with mumps vaccine:
postvaccinal parotitis and aseptic meningitis (114). The
incidences of those side effects significantly differ from
vaccine to vaccine. Generally vaccines developed from
Japanese and Russian strains are significantly more
neurovirulent and have significantly higher incidence of
aseptic meningitis than JL and RIT4385 based ones
(106). The incidence of aseptic meningitis ranged from 1
case per 1000 vaccinated for Japanese strains (Urabe
Am9, Hoshino, Torii) to 1 case per 100 000 vaccinated
with JL vaccine (116, 117). Neurovirulence of LZ was
first observed in Slovenia in 1989 where the incidence of
aseptic meningitis after primovaccination with this
strain was calculated as 48 cases per 100 000 vaccinated
(118). Calculating the incidence of aseptic meningitis
after the primovaccination with LZ among the Croatian
infants considering only virologically confirmed cases,
Te{ovi} found the incidence to be 49 cases per 100 000
vaccinated (119). However, regardless of the severity of
acute illness, no permanent neurologic sequellae were
found among children suffering from aseptic meningitis
after vaccination with LZ (106).
Long-term use of vaccines against mumps in Croatia
has significantly reduced the morbidity of this disease
and established a stable epidemiological situation.
Although reactogenic, LZ is, due to Croatian experience,
undoubtedly efficacious strain (24, 102, 106). However,
in January 2009 LZ was removed from primovaccination
and replaced by the RIT4385 based MMR vaccine (92).
From the beginning of 2012 LZ is no longer in use
neither for revaccination – JL containing MMR vaccine
became constituent part of CVP in Croatia. In con-
clusion, one efficacious but reactogenic vaccine is re-
placed by vaccines that showed high efficacy and low
reactogenicity through their widely use in many regions
of the world. In situation when reemergence of epidemic
mumps is reported even in nations with long-term two-
-doses vaccination schedule, maintaining a high vaccinal
coverage is highly desirable (120-122).
Vaccination against rubella
Rubella is a benign systemic viral disease characte-
rised with mild fever, malaise and maculopapular rash.
20% to 50% of infected subjects have minimal or no
clinical symptoms and complications of disease (ence-
phalitis, thrombocytopenia) are rare (123). Typically, a
mild childhood disease, rubella in pregnancy can result
in miscarriage, stillbirth or an infant born with conge-
nital rubella syndrome (CRS) which comprises deafness,
heart disease, cataracts and other permanent congenital
manifestations (124). The elimination of rubella and
prevention of congenital rubella infection in Europe has
been a high priority for the WHO European Regional
Office for the past 10 years. In 2002 a strategic plan was
developed and implemented for the prevention of conge-
nital rubella infection with the target of <1 case of CRS
per 100 000 live births by 2010 (125). Three years later the
strategy was revised to include rubella elimination by
2010, defined as <1 indigenous case per 1 000 000 (126).
In September 2010 the WHO regional committee for
Europe renewed its commitment to the elimination of
rubella and prevention of CRS with the new target of
2015 (127). A highly effective attenuated live rubella
vaccine was developed over thirty years ago (123). All
vaccines produced worldwide with the exception of Japa-
nese ones contain RA 27/3 strain developed on human
diploid fibroblasts (128). RA 27/3 is adopted because of
its consistent immunogenicity, induction of resistance to
reinfection, and a low rate of side effects (128). Conti-
nuous universal use of two-dose vaccination schedule
with 98% coverage rate resulted in an excellent control of
infection and elimination of CRS (24, 124). In the last
decade, with the exception of 2007 when a limited out-
break with 39 cases were recorded, no more than 10
subjects with rubella have been reported to CNIPH (24).
In the same period no CRS cases have been reported
from Croatia (124).
VACCINATION FOR CHILDREN AT RISK
According to Croatian legislation, the vaccination
against influenza, pneumococcal disease and rotavirus
infection is recommended for certain groups of children
at risk (129).
Vaccination against influenza
Influenza is a serious infectious disease that continues
to contribute to significant morbidity and mortality
worldwide. Yearly influenza vaccination benefits have
been demonstrated and vaccination for high-risk groups
is well recognised in Europe and the rest of the world as a
means of preventing infection and its complications
(130). High risk groups for for influenza complications
include elderly (>65 years of age) as well as infants and
children with existing health complications and vac-
cination of these groups is a current practice in many
countries (130). Although some countries (US, Canada)
recommend universal vaccination of healthy children,
this practice is not widespread in Europe despite clear
demonstration of the benefits of vaccination in reducing
the large health and economic burden of influenza (130,
131). In Europe only six countries (Austria, Estonia,
Finland, Latvia, Romania, Slovakia, Slovenia) advise
routine vaccination for all children (130). The rest of the
Europe, including Croatia recommend vaccination of
high-risk populations of children that include patients
with chronic pulmonary and cardiovascular diseases,
with haematological or metabolic disorders, immuno-
logical disorders and chronic renal diseases (130). The
two doses of trivalent inactivated influenza vaccine con-
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taining one influenza A(H3N2) strain, one influenza
A(H1N1) strain and one influenza B strain are admini-
stered at least one month apart for children aged 6 months
to 8 or 9 years (depending on manufacturer’s recom-
mendations) who either receive an influenza vaccine for
the first time or have not been exposed to influenza
previously. For children under 3 years of age a half dose is
required per injection. For older children receiving the
seasonal influenza vaccine for the first time, a single dose
of the vaccine is appropriate (130).
The efficacy and effectiveness of trivalent inactivated
vaccine (TIV) in healthy children (under 19 years of age)
has been examined in a number of meta-analyses, and
the overall vaccine efficacy estimates were similar for
laboratory confirmed influenza (59-63%) and clinical
cases (36-45%) (132, 133). For children aged less than 5
years the vaccine efficacy against influenza is broad
ranging, from 12 to 83% (134). The inactivated influenza
vaccine is safe and well-tolerated in children (130).
Vaccination against pneumococcal
disease
Streptococcus pneumoniae (pneumococcus) is the most
important bacterial pathogen in children younger than 5
years. Pneumococcus frequently colonizes the nasal mu-
cosa of children and adults, especially during the winter
months. Up to 70% of children who attend day care are
colonized with pneumococci during the colder part of
the year (135). Pneumococcus in humans causes a wide
range of different diseases. Non-invasive (mucosal)
diseases – acute otitis media (AOM), pneumonia and
sinusitis, are more common than invasive. Invasive pne-
umococcal diseases (IPD) are characterized by the pene-
tration of pneumococci from the respiratory mucosa into
the bloodstream or other primary sterile sites (cerebro-
spinal fluid, pleural, peritoneal, or articular cavity). Of
all the IPDs, the most common is occult bacteremia
characterised by fever, chills, and leukocytosis, frequent-
ly without concomitant other signs of disease (135, 136).
Significant differences in the incidence of IPD in
various parts of the world exist. Prior to the introduction
of the universal active immunization among children
younger than two years the incidence of IPD in US
amounted to 188 cases IPB per 100 000 children annual-
ly. In Western Europe, the incidence of IPD is signifi-
cantly lower and amounts to 30-90 patients per 100 000
children younger than 2 years per year. Notwithstanding
the significant differences in incidence, IPD is now in all
parts of the world the most common invasive bacterial
disease in young children. Although more than 90 dif-
ferent pneumococcal serotypes exist, the majority of IPD
cases in children occur as a result of infection by the
different serotypes. Newly developed pneumococcal
conjugate vaccines (PCV), which contain ten (10PCV)
or thirteen (13PCV) different capsular antigens, can thus
prevent most cases of IPD. Although often affecting
healthy children, the incidence of IPD is higher in
patients with certain chronic conditions / diseases like
those with congenital heart disease, chronic lung, kidney
and liver disease, cerebrospinal fluid leaks, children with
cochlear implants and children with congenital and
acquired immunodeficiencies (137-141).
In Croatia the incidence of IPD is highest among
children younger than 2 years – 36.8 / 100 000 children
per year (95% CI 27.7 to 48.9). In children aged 2-5 years
the incidence of IPD is 16.3 / 100 000 (95% CI 11.5 to
22.9), while in those older than 5 years the incidence of
IPD is 2.9 / 100 000 (95% CI 1 0.8 to 4.6) (Table 2.) (142).
The most common serotypes are 14, 6B, 18 F and 23F,
which account for 67% of the isolates. Analyzing the
vaccine coverage of pneumococcal isolates taking into
account their serodistribution it could be calculated that
the majority of IPD cases in Croatia could be prevented
using 10PCV or 13PCV (Table 3.) (141, 142).
However, use of PCV only for children at increased
risk for developing IPD will not significantly affect the
incidence of disease in the entire Croatian population.
Experience from countries that have introduced uni-
versal immunization with PCV has showed, however,
that the PCV significantly reduces the incidence of IPV
not only among vaccine recipients, but also in the non-
immunized rest of the population (141, 143, 144). Ano-
ther interesting observation from nations who imple-
mented vaccination for the whole population of infants
is that the universal usage of PCV significantly reduced
the number of non-invasive forms of pneumococcal di-
sease such as AOM and pneumonia (141, 145). Although
the favourable effect of PCV on the epidemiology of IPD
is not questionable, bearing in mind the differences in
the composition of available vaccines, before a final
decision on the introduction of certain PCV in the natio-
nal immunization program is made, careful seroepi-
demiological study in each population should be done,
as a prerequisite for the selection of an optimal vaccine
(146).
Vaccination against rotavirus infection
Rotavirus (RV) is a major cause of infectious diarr-
hoea in children less than 5 years of age worldwide,
responsible for more than 140 million episodes annually
(147). In developed nations community-acquired RV
(CARV) infection is an important cause of morbidity in
primary healthy children, with a significant impact on
the total medical costs. Concurrently, nosocomial RV
(NRV) infections represent a major component of hospi-
tal-acquired infections in children (31–87% of all noso-
comial enteric infections) causing significant prolonga-
tion of hospitalization and increasing the amount of
medical costs (147–151). Both CARV and NRV are cha-
racterised by seasonality which is especially expressed in
temperate climate zones and peak of incidence coincides
with cooler part of the year (from November to May) (147,
152, 153). Although numerous different types of RV exist,
the majority of human infections are caused by a limited
number of strains belonging to group A geno/ serotypes
(154). No more than 4 RV serotypes: (G1P[8], G2P[4],
G3P[8] and G4P[8]), have been linked to 90–95% of all
hospitalized RV cases in Europe (154-156).
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RV gastroenteritis is a highly contagious disease trans-
mitted by fecal-oral route. The usual precaution mea-
sures are ineffective in transmission control. Breastfeed-
ing also does not contribute to the protection against
infection / disease caused by RV. Vaccination, thus re-
mains the only effective preventive measure in reducing
the burden of RV infection (147). The development of
both oral RV live-attenuated vaccines currently available
on the market – pentavalent human-bovine reassortant
vaccine (RV5) and monovalent human vaccine (RV1)
was based on the observation that natural infection could
serve as an immunizing process. Namely, after primary
infection with wild RV strains, the probability for re-
infection with any genotype of the virus is reduced by
40%. Previous RV infection reduces the likelihood for
symptomatic reinfection by 75% and the probability that
the next RV infections would cause severe gastroenteritis
for 88% (157). Immunogenicity, reatogenicity and efficacy
of both vaccines were tested in numerous prelicensure
studies that included more than 100 000 vaccinees. All
studies showed good immunogenicity and low reactoge-
nicity (156). Later experiences from nations that included
RV vaccines into their national immunization programs
further confirmed the previous observations (158, 159,
160). Universal immunization against RV infection sig-
nificantly reduced the number of diarrheal episodes as
well as the number of hospitalizations (158, 159). Although
regional differences in the distribution of serotypes exist it
seems that both vaccines give excellent protection against
RV disease, especially against severe forms (154, 158,
159).
In Croatia, the active immunization against RV infec-
tion was introduced in 2011 just for certain risk popu-
lations: 1. prematures born before the end of the 33rd
week of gestation; 2. infants with congenital heart de-
fects; 3. infants with congenital metabolic disorders; 4.
infants with chronic liver and kidney diseases and 5.
infants with serious neurological damage (129). Infants
should be vaccinated within the first six months of age
with two (for RV1) or three (for RV5) doses of vaccine.
First dose of vaccine should be applied after the age of six
weeks (129).
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TABLE 2
The incidence of invasive pneumococcal disease (IPD) in Croatian children younger than 14 years in years 2001, 2005 and
2006*
Year Age (year) Estimated population Incidence of IPD 95% CI
2001 <2 38 948 33.9 19.7-58.4
2-5 69 045 11.8 5.9-25.5
5-14 232 347 2.2 0.9-5.2
2005 <2 40 066 34.7 20.9-57.7
2-5 66 410 14.3 7.4-27.5
5-14 241 117 3.1 1.4-6.5
2006 <2 47 056 41.0 26.4-63.5
2-5 66 609 22.2 13.6-36.3
5-14 240 158 3.5 1.7-7.4




142. GU@VINEC M, TE[OVI] G, TAMBI]-ANDRA[EVI] A, @IDOVEC-LEPEJ S, TRO[ELJ VUKI], B, BEGOVAC J 2008 Epidemiology of
invasive Streptococcus pneumoniae disease in Croatian children. Med Sci Monit 14: PH59-64
TABLE 3
Analysis of vaccinal coverage of pneumococcal serotypes that caused invasive pneumococcal disease by conjugate
vaccines registerred in Croatia**
2001/06 2007/09
vaccine Number of isolates (%) Number of isolates (%) p-value*
10 PCV 83 (83,0) 95 (74,2) 0,32 (NS)
13 PCV 90 (90,0) 112 (87,5) 0,77 (NS)
*Fisher- exact test
NS – statistically nonsignificant
**Acording to: 141. TE[OVI] G, GU@VINEC M, TAMBI]-ANDRA[EVI] A 2011 Invazivna pneumokokna bolest u djece. Pediatr Croat 55: 75-80
CONCLUSION
The immunization program in Croatia has been bas-
ed on mandatory vaccinations for more than 60 years.
Since the introduction of the first vaccines against diph-
theria and tuberculosis in 1948, the program has under-
gone many changes and improvements, particularly in
the last decade. The favourable impact of vaccination on
the epidemiology of infectious diseases in Croatia is im-
mense. Thanks to the continuous vaccination with high
coverage rates some diseases, like poliomyelitis, measles,
rubella, CRS and invasive Hib disease have disappeared
or are about to disappear from Croatian population.
Although the CVP in Croatia is undoubtedly effective
and based on modern vaccines, further adjustments and
the introduction of new vaccines, particularly vaccines
against IPD and RV infection is highly desirable.
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